

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 11

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned <i>NICHOLS</i>
Attorney Docket Number	15270J-004743US

O I P E

JCS

AUG 20 2001

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	196	6,150,091		Pandolfo et al.	11-21-2000	_____
	1	6,057,367		Stamler et al.	05-02-2000	_____
	2	5,958,683		Snow	09-28-1999	_____
	3	5,955,317		Suzuki et al.	09-21-1999	_____
	4	5,955,079		Mond et al.	09-21-1999	_____
	5	5,877,399		Hsiao et al.	03-02-1999	_____
	6	5,869,093		Weiner et al.	02-09-1999	_____
	7	5,869,054		Weiner et al.	02-09-1999	_____
	8	5,854,204		Findels et al.	12-29-1998	_____
	9	5,851,998		Kline	12-22-1998	_____
	10	5,849,268		Weiner et al.	12-15-1998	_____
	11	5,837,473		Maggio et al.	11-17-1998	_____
	12	5,786,180		Konig et al.	07-28-1998	_____
	207	5,780,587		Potter	07-14-1998	_____
	13	5,753,624		McMichael et al.	05-19-1998	_____
	14	5,750,349		Suzuki et al.	05-12-1998	_____
	197	5,744,368		Goldgaber et al.	04-28-1998	_____
	211	5,738,142		Sette et al.	04-07-1998	_____
	15	5,733,547		Weiner et al.	03-31-1998	_____
	16	5,688,651		Solomon	11-18-1997	_____
	17	5,679,348		Nesburn et al.	10-21-1997	_____
	18	5,645,820		Hafler et al.	07-08-1997	_____
	19	5,641,474		Hafler et al.	06-24-1997	_____
	20	5,641,473		Hafler et al.	06-24-1997	_____
	21	5,612,486		McConlogue et al.	03-18-1997	_____
	22	5,605,811		Seubert et al.	02-25-1997	_____
	23	5,585,100		Mond et al.	12-17-1996	_____
	24	5,571,500		Hafler et al.	11-05-1996	_____
	25	5,571,499		Hafler et al.	11-05-1996	_____
	175	5,441,870		Saubert, et al.	08-15-1995	_____
	26	5,434,170		Andrulis, Jr.	07-18-1995	_____
	27	5,387,742		Cordell	02-07-1995	_____
	181	5,270,165		Van Nostrand et al.	12-14-1993	_____
	28	5,231,000		Majocha et al.	07-27-1993	_____
	29	5,220,013		Ponte et al.	06-15-1993	_____

Examiner Signature

G. Nichols

Date Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheets 2

of 11

C mplet If Kn wn

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned <i>NICHOLS</i>
Attorney Docket Number	15270J-004743US

AUG 20 2001

	30	5,208,036	_____	Eppstein et al.	05-04-1993	_____
<i>CD</i>	31	5,192,753	_____	McGeer et al.	03-09-1993	_____
<i>CD</i>	32	5,187,153	_____	Cordell et al.	02-16-93	_____
<i>CD</i>	33	5,057,540	_____	Kensil et al.	10-15-1991	_____
<i>CD</i>	198	5,004,697	_____	Pardridge	04-02-1991	_____
<i>CD</i>	34	4,666,829	_____	Glenner et al.	05-19-1987	_____

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>CD</i>	35	EP	911 036	A2	_____	04-28-1999	_____	<input type="checkbox"/>
<i>CD</i>	36	EP	868 918	A2	_____	10-07-1998	_____	<input type="checkbox"/>
<i>CD</i>	37	EP	863 211	A1	_____	09-09-1998	_____	<input type="checkbox"/>
<i>CD</i>	38	EP	845 270	A1	_____	06-03-1998	_____	<input type="checkbox"/>
<i>CD</i>	39	EP	782 859	A1	_____	07-09-1997	_____	<input type="checkbox"/>
<i>CD</i>	40	EP	683 234	A1	_____	11-22-1995	_____	<input type="checkbox"/>
<i>CD</i>	41	EP	666 080	A1	_____	08-09-1995	_____	<input type="checkbox"/>
<i>CD</i>	42	EP	652 962	B1	_____	12-16-1998	_____	<input type="checkbox"/>
<i>CD</i>	43	EP	639 081	B1	_____	11-03-1999	_____	<input type="checkbox"/>
<i>CD</i>	44	EP	613 007	A2	_____	08-31-1994	_____	<input type="checkbox"/>
<i>CD</i>	45	EP	594 607	B1	_____	08-27-1997	_____	<input type="checkbox"/>
<i>CD</i>	46	EP	581 087	B1	_____	08-04-1999	_____	<input type="checkbox"/>
<i>CD</i>	47	EP	528 511	B1	_____	05-28-1997	_____	<input type="checkbox"/>
<i>CD</i>	48	EP	508 785	B1	_____	03-15-2000	_____	<input type="checkbox"/>
<i>CD</i>	49	EP	451 700	A1	_____	10-18-1991	_____	<input type="checkbox"/>
<i>CD</i>	50	EP	440 619	B1	_____	01-24-1996	_____	<input type="checkbox"/>
<i>CD</i>	51	EP	359 783	B1	_____	11-29-1995	_____	<input type="checkbox"/>
<i>CD</i>	52	EP	276 723	B1	_____	12-08-1993	_____	<input checked="" type="checkbox"/>
<i>CD</i>	187	EP	783 104	A1	_____	07-09-1997	_____	<input type="checkbox"/>
<i>CD</i>	199	PCT	00/77178	A1	_____	12-21-2000	_____	<input type="checkbox"/>
<i>CD</i>	188	PCT	00/43049	A1	_____	07-27-2000	_____	<input type="checkbox"/>
<i>CD</i>	53	PCT	99/60024	A1	_____	11-25-1999	_____	<input type="checkbox"/>
<i>CD</i>	54	PCT	99/60021	A2	_____	11-15-1999	_____	<input type="checkbox"/>
<i>CD</i>	55	PCT	99/58564	A1	_____	11-18-1999	_____	<input type="checkbox"/>
<i>CD</i>	56	PCT	99/60666	A2	_____	02-11-1999	_____	<input type="checkbox"/>
<i>CD</i>	57	PCT	99/27949	A1	_____	06-10-1999	_____	<input type="checkbox"/>
<i>CD</i>	58	PCT	99/27944	A1	_____	06-10-1999	_____	<input type="checkbox"/>

Examiner Signature

Guilfoyle

Date Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

AUG 20 2001 (use as many sheets as necessary)


Sheet 2

of 11

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned - Nichols
Attorney Docket Number	15270J-004743US

59	PCT	99/27811	A1	06-10-1999	
203	PCT	99/00150	A2	01-07-1999	
60	PCT	98/44955	A1	10-15-1998	
61	PCT	98/07850	A2	02-26-1998	
202	PCT	97/21728	A1	08-19-1997	
62	PCT	97/17613	A1	05-15-1997	
63	PCT	96/39176	A1	12-12-1996	
208	PCT	96/28471	A1	09-19-1996	
64	PCT	96/25435	A1	08-22-1996	
65	PCT	96/18900	A1	06-20-1996	
66	PCT	95/31896	A1	11-30-1995	
200	PCT	95/12815	A1	05-11-1995	
67	PCT	95/11894	A1	05-04-1995	
68	PCT	95/11311	A1	04-27-1995	
69	PCT	95/05853	A1	03-02-1995	
70	PCT	95/04151	A2	02-09-1995	
201	PCT	94/28412	A1	12-08-1994	
71	PCT	94/03815	A1	02-17-1994	
72	PCT	94/01772	A1	01-20-1994	
73	PCT	93/21850	A1	11-11-1993	
74	PCT	93/18724	A1	09-02-1993	
75	PCT	93/15760	A1	08-19-1993	
76	PCT	93/14200	A1	07-22-1993	
205	PCT	93/04194	A1	03-04-1993	
77	PCT	93/02189	A1	02-04-1993	
78	PCT	92/13089	A1	08-06-1992	
79	PCT	92/06708	A1	04-30-1992	
80	PCT	92/06187	A1	04-16-1992	
81	PCT	91/19810	A1	12-26-1991	
82	PCT	91/16819	A1	11-14-1991	
83	PCT	91/12816	A1	09-05-1991	
84	PCT	91/08780	A1	08-27-1991	
85	PCT	90/12871	A1	11-01-1990	
86	PCT	90/12870	A1	11-01-1990	
87	PCT	89/01343	A1	02-23-1989	
88	PCT	89/08242	A1	07-13-1989	
89	PCT	89/06689	A1	07-27-1989	
90	PCT	89/03687	A1	05-05-1989	
91	PCT	88/10120	A1	12-29-1988	

Examiner
Signature



Date
Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 11

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned - <i>NICHOLS</i>
Attorney Docket Number	15270J-004743US

92	GB	2 220 211	A	=====	01-04-1990	=====	□
93	GB	2 335 192	A	=====	09-15-1999	=====	□



Examiner Signature	<i>G. Nichols</i>	Date Considered	4/14/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box → **+**

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

AUG 20 2001

(use as many sheets as necessary)

PATENT & TRADEMARK OFFICE

Sheet 5 of 11

C mplete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned → NO CHOLS
Attorney Docket Number	15270J-004743US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995).	<input type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).	<input type="checkbox"/>
	98	BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	<input type="checkbox"/>
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> 18:764 (1992).	<input type="checkbox"/>
	178	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet. Develop.</u> , 3: 102-109 (1993).	<input type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	<input type="checkbox"/>
	102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).	<input type="checkbox"/>
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> 125:223-226 (1991).	<input type="checkbox"/>
↓	214	DEMATTOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).	<input type="checkbox"/>
CS	103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).	<input type="checkbox"/>

Examiner Signature

Guille B

Date Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6 of 11

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned. NICHOLS
Attorney Docket Number	15270J-004743US

CIPR
JC6

AUG 20 2001

104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983). <input type="checkbox"/>
105	FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993). <input type="checkbox"/>
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996). <input type="checkbox"/>
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991). <input type="checkbox"/>
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995). <input type="checkbox"/>
210	FRIEDLAND et al., "Development of an anti- $\text{A}\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994). <input type="checkbox"/>
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995). <input type="checkbox"/>
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $\text{A}\beta_{1-42}$," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000). <input type="checkbox"/>
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992). <input type="checkbox"/>
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993). <input type="checkbox"/>
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998). <input type="checkbox"/>
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1984). <input type="checkbox"/>
114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984). <input type="checkbox"/>
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991). <input type="checkbox"/>
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996). <input type="checkbox"/>
190	GRAVINA et al., "Amyloid β Protein ($\text{A}\beta$) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995). <input type="checkbox"/>
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343. (1997). <input type="checkbox"/>
118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993). <input type="checkbox"/>

Examiner
Signature*Grill*Date
Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet

7 of 11

C mpt te If Kn wn	
Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned <i>NICHOLS</i>
Attorney Docket Number	15270J-004743US

AUG 20 2001



	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	<input type="checkbox"/>
	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	<input type="checkbox"/>
	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	<input type="checkbox"/>
	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	<input type="checkbox"/>
	177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	<input type="checkbox"/>
	122	HSIAO et al., "Correlative Memory Deficits, $\text{A}\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	<input type="checkbox"/>
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	<input type="checkbox"/>
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	<input type="checkbox"/>
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	<input type="checkbox"/>
	192	IWATSUBO et al., "Visualization of $\text{A}\beta$ 42(43) and $\text{A}\beta$ 40 in Senile Plaques with End-Specific $\text{A}\beta$ Monoclonals: Evidence That an Initially Deposited Species Is $\text{A}\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).	<input type="checkbox"/>
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	<input type="checkbox"/>
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991).	<input type="checkbox"/>
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	<input type="checkbox"/>
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	<input type="checkbox"/>
	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	<input type="checkbox"/>
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	<input type="checkbox"/>
<i>CDW</i>	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	<input type="checkbox"/>
<i>CDW</i>	130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	<input type="checkbox"/>

Examiner
Signature*Guineas*Date
Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8 of 11

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned <i>NICHOLS</i>
Attorney Docket Number	15270J-004743US

O P I E
J.C.

AUG 20 2001

PATENT & TRADEMARK OFFICE

131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).	<input type="checkbox"/>
132	LEMERÉ et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	<input type="checkbox"/>
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).	<input type="checkbox"/>
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).	<input type="checkbox"/>
216	MAJOCZA et al., "Development of a Monoclonal Antibody Specific for β A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).	<input type="checkbox"/>
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	<input type="checkbox"/>
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).	<input type="checkbox"/>
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).	<input type="checkbox"/>
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).	<input type="checkbox"/>
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	<input type="checkbox"/>
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	<input type="checkbox"/>
140	PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).	<input type="checkbox"/>
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	<input type="checkbox"/>
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1984).	<input type="checkbox"/>
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	<input type="checkbox"/>
144	RASO, V.A., Grant application # 1 P43 AG15746-01, (publication date unknown).	<input type="checkbox"/>

CROSS-REFERENCED TO PCT PRINT

Examiner
Signature*Guile*Date
Considered

4/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of 11

C mpt te if Kn wn

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned - NICHOLS
Attorney Docket Number	15270J-004743US

AUG 20 2001

PATENT & TRADEMARKS

145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	<input type="checkbox"/>
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	<input type="checkbox"/>
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	<input type="checkbox"/>
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	<input type="checkbox"/>
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	<input type="checkbox"/>
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	<input type="checkbox"/>
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	<input type="checkbox"/>
151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	<input type="checkbox"/>
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	<input type="checkbox"/>
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	<input type="checkbox"/>
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	<input type="checkbox"/>
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	<input type="checkbox"/>
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	<input type="checkbox"/>
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	<input type="checkbox"/>
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	<input type="checkbox"/>

Examiner
Signature

G. Miller

Date
Considered

4/14/04

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Substitute for form 1449A/PTO

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned - Nichols

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 11

Attorney Docket Number 15270J-004743US

159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997). <input type="checkbox"/>
160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996). <input type="checkbox"/>
161	<u>SOLOMON, A.</u> "Pro Rx (Protein Therapeutics)." University of Tennessee Medical Center (publication date unknown). <input type="checkbox"/>
162	<u>SOLOMON, B.</u> "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response." Department of Molecular Microbiology & Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown). <input type="checkbox"/>
182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996). <input type="checkbox"/>
184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997). <input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1998). <input type="checkbox"/>
186	<u>SOLOMON et al.</u> "Activity of monoclonal antibodies in prevention of <i>in vitro</i> aggregation of their antigens." abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). <input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996). <input type="checkbox"/>
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997). <input type="checkbox"/>
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997). <input type="checkbox"/>
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998). <input type="checkbox"/>
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994). <input type="checkbox"/>
167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994). <input type="checkbox"/>
168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994). <input type="checkbox"/>
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994). <input type="checkbox"/>
180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994). <input type="checkbox"/>
170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 895-700 (1997). <input type="checkbox"/>

CONSIDERED; DO NOT PRINT.

Examiner Signature	<i>G. Nichols</i>	Date Considered	4/14/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11

of 11

C mplete If Known	
Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned N (47045)
Attorney Docket Number	15270J-004743US


AUG 20 2000

5

PATENT & TRADEMARKS

171	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):485-476 (1998).
172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-824 (2000).
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).
173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).
174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).

CONSIDERED; DO NOT PRINT.

Examiner Signature		Date Considered	4/14/04
--------------------	---	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3164980 v1

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,319
(use as many sheets as necessary)				Filing Date	November 27, 2000
Sheet	1	of	6	First Named Inventor	Schenk, Dale B.
				Group Art Unit	1647
				Examiner Name	Tanner, Sheron NICHOLS
				Attorney Docket Number	15270.J-004743US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cita No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
CP	287	8,294,171	B2	McMichael	08-25-2001
	234	8,284,221	B1	Schenk, et al.	08-04-2001
	300	2001/0018058	A1	McMichael	08-30-2001
	230	8,262,335	B1	Msiao et al.	07-17-2001
✓	231	6,114,133		Seubert et al.	09-05-2000
CP	221	5,969,566		Cobb et al.	11-23-1999
CP	284	5,231,170		Averbach	07-27-1993
	343	56168,504		Charlton et al.	N/A
	282	66/169,887		Chen	N/A
	256	66/184,601		Holtzman et al.	N/A
	259	66/188,295		Rosenquist et al.	N/A
	295	66/254,488		Holtzman et al.	N/A
	297	66/254,488		Holtzman et al.	N/A
	203	66/141,140		Solomon et al.	N/A

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cita No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴		
CP	243	PCT	01/39788	A2	08-07-2001
	298	PCT	01/42308	A2	08-14-2001
	601	PCT	01/62284	A2	03-01-2000
	294	PCT	01/62801	A2	08-30-2001
✓	240	PCT	00/43039	A1	07-27-2000
CP	227	PCT	95/11008	A2	04-27-1995

BEST AVAILABLE COPY

Examiner Signature	<i>Grub</i>	Date Considered	4/14/04
--------------------	-------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21

CONSIDERED; DO NOT PRINT.

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box →

PTO/SB/088 (06-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6


Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Turner, Sharon NICHOLS
Attorney Docket Number	15270J-00473US

+

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	CJA	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease, Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 226(4): 1075-1083 (1992).
	238	BEASLEY, "Alzheimer's traced to proteins caused by aging," <i>Reuters</i> , April 20, 2001 7:58 PM ET.
	205	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992).
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, "Information on Vaccines (Mercury in Thimerosal-Containing Products), web site currently found at: http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 08, 2002."
	286	CHAPMAN, PAUL F., "Model behavior," <i>Nature</i> , 408:915-916 (2000).
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Additives to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database, (Publication date unknown.)
	302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <i>J. Biol. Chem.</i> , 274(45):52301-52308 (1999).
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <i>Pharm. Res.</i> , 17:268-274 (2000).
	286	CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 34:59-89 (1994).
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <i>Scand. J. Immunol.</i> , 38:177-182 (1993).
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <i>Life Sci.</i> , 63:2121-2121 (1998).
	220	Filed/Granted, Abstract of WPI Acc No. 1997-054438/00700, Stable vaccine comprising a macrocyclic lactone, a milbemycin, an ivermectin, an enrofloxacin, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Document File 151: Danwan/WPI database, (Publication date unknown.)
✓	288	DUMERY et al., " β -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <i>Pathol. Biol.</i> , 49:72-85 (2001).
CJA	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release, (1/26/2002).

+ CONSIDERED; DO NOT PRINT.

Examiner Signature		Date Considered	4/14/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0091

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

6

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Turner, Sharon NICHOLS
Attorney Docket Number	15270J-004743US

BEST AVAILABLE COPY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CSJ	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002).	
	239	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <i>Trends in Pharm. Sci.</i> , 22:2-3 (2001).	
	248	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i> , 19:2615-2619 (2001).	
	247	FRENKEL et al., "Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration," <i>PNAS USA</i> , 97:11455-11459 (2000).	
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuropathology</i> , 59:85-90 (1998).	
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuropathology</i> , 55:136-142 (1996).	
	244	FRENKEL, et al., "Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuropathology</i> , 10:23-31 (2000).	
	249	FREIDLAND, et al., "Neuromaging of Vessel Amyloid in Alzheimer's Disease," In <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hockfield, New York Academy of Sciences, New York, New York (1997).	
	251	GARDAELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <i>Biochem. Biophys. Res. Comm.</i> , 173:1292-1298 (1990).	
	252	GEDDES, "N-terminal truncated beta-amyloid peptides and C-terminal truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <i>Neurobiology of Aging</i> , 20:75-79 (1999).	
	263	GIULIAN, et al., "The MHCK Domain of beta-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>Journal of Biological Chem.</i> , 273:28710-28726 (1998).	
	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 93:149-153 (1998).	
	237	GORTNER, <i>Outline of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
✓	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with beta-amyloid could T-cell activation have a harmful effect?," <i>TINS</i> , 23:114 (2000).	
CS	241	HAASS et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 398(6732):322-5 (1992).	

Examiner Signature

Date Considered

4/14/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. CMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Turner, Sharon NICK HOLS
Attorney Docket Number	15270J-004743US

BEST AVAILABLE COPY

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DS	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 211:1015-1022 (1995).
	228	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2," <i>Immunology</i> , Vol. 78: 843-849 (1995).
	238	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).
	258	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <i>Lab. Invest.</i> , 57:446-449 (1987).
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of β -amyloid precursor protein," <i>Brain Research Protocol</i> , 2:23-30 (1997).
	258	KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of β -peptide in Alzheimer's disease and Down's syndrome brain," <i>Neuroscience Letters</i> , 193:105-108 (1995).
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <i>Curr. Opin. in Chemical Biology</i> , 1:280-287 (1997).
	260	LEMERRE, et al., "Name] $\text{A}\beta$ treatment induces anti- $\text{A}\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <i>Annals of the NY Acad. Sci.</i> , 920:328-331 (2000).
	281	MAK, et al., "Polyclonals to β -amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <i>Brain Research</i> , 667:138-142 (1994).
	283	MANN, et al., "Amyloid β protein ($\text{A}\beta$) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $\text{A}\beta_{42}$," <i>Annals of Neurology</i> , 40:149-158 (1996).
	282	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <i>Neuroscience Letters</i> , 198:105-108 (1995).
	284	McGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <i>J. of Neuroscience Res.</i> , 31:428-442 (1992).
	298	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and OS-21," <i>Virology</i> , 243:158-168 (1998).
DS	265	Mena, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <i>Acta Neuropathol.</i> , 89:50-58 (1995).
DS	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 39:1159-65 (1989).

Examiner Signature

Date Considered

4/14/04

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Turner, Sharon NICHOLS
Attorney Docket Number	15270J-004743US

BEST AVAILABLE COPY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
SD	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995).
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995).
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998).
	235	NEWCOMBE and COHEN, "Solvability characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-485 (1985).
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptides pharmaceutical delivery through the blood-brain barrier," <i>Biochem. Biophys. Res. Comm.</i> , 146:307-313 (1987).
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <i>Laboratory Animal Science</i> , 46(1):8-14 (1996).
	269	PHILIPPE, et al., "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <i>J. of Neuroscience Res.</i> , 40:709-719 (1998).
	270	SAITO et al., "Vector-mediated delivery of 125 I-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β $^{1-40}$ vector complex," <i>PNAS USA</i> , 92:10227-10231 (1995).
	278	SAITO, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <i>Sugaku Med. J.</i> , 80:309-320 (1991).
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <i>Brain Res.</i> , 753:193-201 (1997).
	270	SCHENK, et al., " β -peptide immunization," <i>Arch. Neurol.</i> , 57:934-938 (2000).
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <i>Nature</i> , 40:118-117 (1998).
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on <i>in vitro</i> properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <i>Int. J. Peptide Protein Res.</i> , 47:239-246 (1998).
CD	273	THORSETT, E.D. and L.M. LATIMER, "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000).
CD	278	TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <i>Journal of Biological Chemistry</i> , 271:8545-8548 (1996).

Examiner Signature

Date Considered

4/14/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0091

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

6

Complete If Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1847
Examiner Name	Turner, Sharon NICHOLS
Attorney Docket Number	15270J-004743US

+ CONSIDERED, DO NOT PRINT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	File No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.
CS	274	WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 49:567-578 (2001).
	223	Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Sledgoats," <i>U.S. Govt. Rec. Develop. Rep.</i> , 70(24), 68. (Publication date unknown.)
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>in vivo</i> with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997).
✓	292	YAMAGUCHI et al., "Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <i>Acta Neuropathol.</i> , 83:217-222 (1996).
CS	280	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <i>Nature Medicine</i> , 7:18-19 (2001).

BEST AVAILABLE COPY

Examiner Signature	<i>Turner</i>	Date Considered	4/4/04
--------------------	---------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3243317 v1

PA 3242256 v2

PA 3147648 v21